These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11062762)

  • 1. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals.
    Kostarelos K; Emfietzoglou D
    Anticancer Res; 2000; 20(5A):3339-45. PubMed ID: 11062762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy.
    Emfietzoglou D; Kostarelos K; Sgouros G
    J Nucl Med; 2001 Mar; 42(3):499-504. PubMed ID: 11337529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies.
    Gestin JF; Loussouarn A; Bardiès M; Gautherot E; Gruaz-Guyon A; Saï-Maurel C; Barbet J; Curtet C; Chatal JF; Faivre-Chauvet A
    J Nucl Med; 2001 Jan; 42(1):146-53. PubMed ID: 11197965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
    Cremonesi M; Ferrari M; Chinol M; Bartolomei M; Stabin MG; Sacco E; Fiorenza M; Tosi G; Paganelli G
    Q J Nucl Med; 2000 Dec; 44(4):325-32. PubMed ID: 11302260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.
    Larsen RH; Murud KM; Akabani G; Hoff P; Bruland OS; Zalutsky MR
    J Nucl Med; 1999 Jul; 40(7):1197-203. PubMed ID: 10405142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
    Lubic SP; Goodwin DA; Meares CF; Song C; Osen M; Hays M
    J Nucl Med; 2001 Apr; 42(4):670-8. PubMed ID: 11337558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy.
    Shen S; DeNardo GL; DeNardo SJ; Salako Q; Morris G; Banks D; Yuan A; DeNardo DA
    J Nucl Med; 1996 Jan; 37(1):146-50. PubMed ID: 8543984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides.
    Miller WH; Hartmann-Siantar C; Fisher D; Descalle MA; Daly T; Lehmann J; Lewis MR; Hoffman T; Smith J; Situ PD; Volkert WA
    Cancer Biother Radiopharm; 2005 Aug; 20(4):436-49. PubMed ID: 16114992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
    Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
    Torres LA; Coca MA; Batista JF; Casaco A; Lopez G; García I; Perera A; Peña Y; Hernández A; Sanchez Y; Romero S; Leyva R; Prats A; Fernandez R
    Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model.
    Chen LC; Wu YH; Liu IH; Ho CL; Lee WC; Chang CH; Lan KL; Ting G; Lee TW; Shien JH
    Nucl Med Biol; 2012 Jan; 39(1):35-43. PubMed ID: 21958858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Techniques for loading technetium-99m and rhenium-186/188 radionuclides into pre-formed liposomes for diagnostic imaging and radionuclide therapy.
    Goins B; Bao A; Phillips WT
    Methods Mol Biol; 2010; 606():469-91. PubMed ID: 20013416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
    Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
    J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biokinetic and dosimetric studies of 188Re-hyaluronic acid: a new radiopharmaceutical for treatment of hepatocellular carcinoma.
    Meléndez-Alafort L; Nadali A; Zangoni E; Banzato A; Rondina M; Rosato A; Mazzi U
    Nucl Med Biol; 2009 Aug; 36(6):693-701. PubMed ID: 19647176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta dose point kernels for radionuclides of potential use in radioimmunotherapy.
    Prestwich WV; Nunes J; Kwok CS
    J Nucl Med; 1989 Jun; 30(6):1036-46. PubMed ID: 2738686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.